• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Zimmer Biomet Receives FDA Clearance for Persona® Revision SoluTion™ Femur

    3/7/25 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care
    Get the next $ZBH alert in real time by email

    A Revision Knee Implant Alternative for Patients with Metal Sensitivities

    WARSAW, Ind., March 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of Persona® Revision SoluTion™ Femur, a revision knee implant component offering an alternative for patients with sensitivities to certain metals. The Persona Revision SoluTion Femur, part of the comprehensive Persona Revision Knee System, leverages a proprietary surface-hardening treatment designed to enhance wear performance,1,2 which offers surgeons an array of anatomic components, including tibial and femoral cones with various stem choices to address zonal fixation.

    (PRNewsfoto/Zimmer Biomet Holdings, Inc.)

    "We are pleased to expand our proprietary surface-hardening technology into the revision knee space with FDA clearance of the Persona Revision SoluTion Femur, the first metal alternative option for those with certain metal sensitivities," said Joe Urban, President, Knees at Zimmer Biomet. "We are proud to offer a total revision knee construct with no deliberate addition of the most common metal allergens (Nickel, Cobalt, & Chromium). Metal sensitivity is one of the potential causes of revision procedures, and the Persona Revision SoluTion Femur is yet another innovation that delivers on our commitment to solve the most meaningful challenges in musculoskeletal health."

    Cutaneous metal hypersensitivity affects 10-15 percent of the general population, while prevalence in patients with metallic implants may be as high as 25 percent.3 Patients may experience an immunological reaction against metallic particles (ions) that are released as a result of implant wear or corrosion.4 When exposed to certain metals commonly used in metal knee implants such as nickel, cobalt and chromium, people with these hypersensitivities can experience an inflammatory response, pain and implant loosening that can require a total knee replacement revision procedure.5

    The Persona Revision SoluTion Femur is made solely of a proprietary Tivanium® (Ti-6Al-4V) alloy with more than 17 years of clinical use.6 The alloy is treated with the Ti-Nidium Surface Hardening Process, which results in a strengthened material that demonstrates hardness, comparable to that of metal implants, with enhanced wear performance that provides resistance to particle release.2,7 The new revision femur is offered in standard and plus sizes to address flexion instability and soft tissue balancing while minimizing implant overhang.8,9

    Persona Revision SoluTion Femur will be commercially available in the U.S. in Q3 2025.

    About Zimmer Biomet 

    Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. 

    With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation. 

    For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X / Twitter at www.x.com/zimmerbiomet. 

    Cautionary Statement Regarding Forward-Looking Statements

    This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet's expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet's periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet's filings with the SEC. Forward-looking statements speak only as of the date they are made, and Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this news release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this news release.

    References:

    1. Improved Abrasion Resistance of Nitrogen-Hardened Titanium Alloy Surfaces. Current Topics in Orthopaedic Technology. Zimmer. Vol. 3, No. 6 (1991).
    2. Zimmer ZRR_WA_2537_12
    3. Akila S.,et al. Metal hypersensitivity in total hip and knee arthroplasty: Current concepts. Journal of Clinical Orthopaedics and Trauma. 2018 Jan-Mar;9(1):3-6, 2018.
    4. Podzimek S. Metal hypersensitivity and pro-inflammatory cytokine production in patients with failed orthopedic implants: A case-control study, Clinical Immunology, Volume 245, 2022. https://doi.org/10.1016/j.clim.2022.109152.
    5. Hozack, W. et al. Primary Cementless Hip Arthroplasty with a Titanium Plasma Sprayed Prosthesis. Clinical Orthopaedics and Related Research. 333: 217-25, 1996.
    6. Rossi SMP, et al. Ten-year outcomes of a nitrided Ti-6Al-4V titanium alloy fixed-bearing total knee replacement with a highly crosslinked polyethylene-bearing in patients with metal allergy. The Knee. 2020;27(5):1519-1524.
    7. Improved Abrasion Resistance of Nitrogen-Hardened Titanium Alloy Surfaces. Current Topics in Orthopaedic Technology. Zimmer. Vol. 3, No. 6 (1991).
    8. Royal Perth Hospital Dept. of Medical Engineering and Physics. (2005). Implant Technology and Biomaterials Bulletin: No. 4. Australia. Department of Medical Engineering and Physics.
    9. Shetty, RH. Surface Hardening of Orthopedic Implants. Biomaterials Engineering and Devices. Vol. 2: 191-202 (2000).

    Media 



    Investors

    Heather Zoumas-Lubeski

    445-248-0577

    [email protected]



    Kirsten Fallon

    781-779-5561

    [email protected]



    David DeMartino

    646-531-6115

    [email protected]



    Zach Weiner

    908-591-6955

    [email protected]

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/zimmer-biomet-receives-fda-clearance-for-persona-revision-solution-femur-302395239.html

    SOURCE Zimmer Biomet Holdings, Inc.

    Get the next $ZBH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZBH

    DatePrice TargetRatingAnalyst
    3/23/2026Buy → Neutral
    BTIG Research
    2/20/2026Mkt Perform
    William Blair
    1/9/2026$93.00Neutral → Sell
    Goldman
    1/6/2026Outperform → Mkt Perform
    Raymond James
    1/5/2026$210.00In-line → Outperform
    Evercore ISI
    12/16/2025$100.00Outperform → Neutral
    Robert W. Baird
    11/6/2025$100.00Overweight → Neutral
    Analyst
    9/18/2025$130.00Buy
    Rothschild & Co Redburn
    More analyst ratings

    $ZBH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zimmer Biomet to Release New Data, Highlight Key Innovations at American Academy of Orthopaedic Surgeons Annual Meeting

    Company's Chief Movement Officer, Arnold Schwarzenegger,Will Be Presidential Guest SpeakerWARSAW, Ind., Feb. 25, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced it will unveil new clinical and operational data and showcase its newest innovations at the American Academy of Orthopaedic Surgeons (AAOS) 2026 Annual Meeting. The company's Chief Movement Officer Arnold Schwarzenegger will take center stage as the conference's Presidential Guest Speaker. On Thursday, March 5 at 10:30 a.m. Central Time, Schwarzen

    2/25/26 7:06:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Announces Quarterly Dividend for First Quarter of 2026

    WARSAW, Ind., Feb. 23, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the first quarter of 2026. The cash dividend of $0.24 per share is payable on or about April 30, 2026 to stockholders of record as of the close of business on March 31, 2026. About Zimmer BiometZimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamles

    2/23/26 7:00:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Announces Fourth Quarter and Full-Year 2025 Financial Results

    Fourth quarter net sales of $2.244 billion increased 10.9% on a reported basis, 9.2% on a constant currency1 basis and 5.4% on an organic constant currency1 basisFourth quarter diluted earnings per share were $0.70, a decrease of 41.7%; adjusted1 diluted earnings per share were $2.42, an increase of 4.8%Full-year net sales of $8.232 billion increased 7.2% on a reported basis, 6.4% on a constant currency1 basis and 3.9% on an organic constant currency1 basisFull-year diluted earnings per share were $3.55, a decrease of 19.9%; adjusted1 diluted earnings per share were $8.20, an increase of 2.5%Company provides full-year 2026 financial guidanceWARSAW, Ind., Feb. 10, 2026 /PRNewswire/ -- Zimmer

    2/10/26 6:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP and CHRO Winkler Lori sold $250,849 worth of shares (2,650 units at $94.66), decreasing direct ownership by 21% to 10,224 units (SEC Form 4)

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    3/16/26 4:12:46 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    Exec VP, CFO Upadhyay Suketu covered exercise/tax liability with 6,576 shares and converted options into 14,776 shares, increasing direct ownership by 13% to 69,485 units (SEC Form 4)

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    3/10/26 4:13:13 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    Group Pres, EMEA Van Zuilen Wilfred converted options into 7,004 shares and covered exercise/tax liability with 1,822 shares, increasing direct ownership by 20% to 30,991 units (SEC Form 4)

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    3/10/26 4:09:32 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Zimmer Biomet Holdings Inc.

    SCHEDULE 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

    3/27/26 2:15:50 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    SEC Form 144 filed by Zimmer Biomet Holdings Inc.

    144 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

    3/12/26 12:04:48 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    SEC Form SCHEDULE 13G filed by Zimmer Biomet Holdings Inc.

    SCHEDULE 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

    2/17/26 5:08:28 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Zimmer Biomet downgraded by BTIG Research

    BTIG Research downgraded Zimmer Biomet from Buy to Neutral

    3/23/26 8:28:29 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    William Blair initiated coverage on Zimmer Biomet

    William Blair initiated coverage of Zimmer Biomet with a rating of Mkt Perform

    2/20/26 8:25:46 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet downgraded by Goldman with a new price target

    Goldman downgraded Zimmer Biomet from Neutral to Sell and set a new price target of $93.00

    1/9/26 8:52:52 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Jafry Syed A. bought $223,641 worth of shares (2,135 units at $104.75), increasing direct ownership by 111% to 4,060 units (SEC Form 4)

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    11/13/23 4:02:02 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    Begley Christopher B bought $117,114 worth of shares (1,000 units at $117.11), increasing direct ownership by 39% to 3,540 units (SEC Form 4)

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    9/29/23 4:05:41 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Financials

    Live finance-specific insights

    View All

    Zimmer Biomet Announces Quarterly Dividend for First Quarter of 2026

    WARSAW, Ind., Feb. 23, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the first quarter of 2026. The cash dividend of $0.24 per share is payable on or about April 30, 2026 to stockholders of record as of the close of business on March 31, 2026. About Zimmer BiometZimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamles

    2/23/26 7:00:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Announces Fourth Quarter and Full-Year 2025 Financial Results

    Fourth quarter net sales of $2.244 billion increased 10.9% on a reported basis, 9.2% on a constant currency1 basis and 5.4% on an organic constant currency1 basisFourth quarter diluted earnings per share were $0.70, a decrease of 41.7%; adjusted1 diluted earnings per share were $2.42, an increase of 4.8%Full-year net sales of $8.232 billion increased 7.2% on a reported basis, 6.4% on a constant currency1 basis and 3.9% on an organic constant currency1 basisFull-year diluted earnings per share were $3.55, a decrease of 19.9%; adjusted1 diluted earnings per share were $8.20, an increase of 2.5%Company provides full-year 2026 financial guidanceWARSAW, Ind., Feb. 10, 2026 /PRNewswire/ -- Zimmer

    2/10/26 6:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Announces Webcast and Conference Call of Fourth Quarter 2025 Financial Results

    WARSAW, Ind., Jan. 15, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced its fourth quarter earnings conference call will be webcast on Tuesday, February 10, 2026, at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. A live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call. Individuals in the U.S. and Canada who wish to d

    1/15/26 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Leadership Updates

    Live Leadership Updates

    View All

    Zimmer Biomet Announces New Chief Medical Advisors to Help Improve Standard of Musculoskeletal Care

    Dr. Jonathan M. Vigdorchik Named Chief Medical Technology Advisor, Adult Reconstruction and Hip Implants Dr. Anand M. Murthi Appointed Chief Medical Advisor, Shoulder, Sports, Extremities, and Trauma (S.E.T.) WARSAW, Ind., Aug. 28, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointments of Jonathan M. Vigdorchik, MD, as Chief Medical Technology Advisor focused on Adult Reconstruction and Hip Implants, and Anand M. Murthi, MD, FAAOS, as Chief Medical Advisor, Shoulder, Sports, Extremities, and Trauma (S.E.T.). As strategic advisors, Drs. Vigdorchik and Murthi will leverage their extensive clinical experience t

    8/28/25 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Appoints Kevin Thornal as Group President, Global Businesses and the Americas

    WARSAW, Ind., May 27, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Kevin Thornal as Group President, Global Businesses and the Americas. Reporting to Chairman-Elect, President and CEO Ivan Tornos, Mr. Thornal will join the Company on July 1, 2025 to oversee the Americas commercial organization and lead business strategy and execution for its global Knees, Hips, S.E.T. and Data, Technology, and Enabling Solutions units. "Kevin is an incredible addition to our leadership team at an e

    5/27/25 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Names Kristen Cardillo as Senior Vice President, Chief Communications Officer

    WARSAW, Ind., March 6, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Kristen Cardillo as Senior Vice President, Chief Communications Officer. Reporting to President and CEO Ivan Tornos, Ms. Cardillo will join the Company on March 10, 2025, to lead Zimmer Biomet's global communications strategy, enhancing engagement with key stakeholders and amplifying the Company's position as a leader in MedTech. "Kristen's expertise in shaping compelling corporate narratives and leading high-impac

    3/6/25 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Zimmer Biomet Holdings Inc.

    SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

    11/14/24 1:22:34 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by Zimmer Biomet Holdings Inc.

    SC 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

    11/13/24 1:44:56 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by Zimmer Biomet Holdings Inc.

    SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

    2/14/24 10:02:59 AM ET
    $ZBH
    Industrial Specialties
    Health Care